Related Experiment Video

Updated: May 31, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

A perspective on cirrhotic cardiomyopathy

T Timoh1, M A Protano, G Wagman

  • 1Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.

Transplantation Proceedings
|June 23, 2011
PubMed

Insights

Cirrhotic cardiomyopathy, a heart condition in cirrhosis patients, involves systolic and diastolic dysfunction. Understanding its cellular basis is key to developing new therapies for heart failure in these individuals.

Area of Science:

  • Cardiology
  • Hepatology
  • Cellular and Molecular Medicine

Background:

  • Cardiac dysfunction is a known complication in cirrhosis patients.
  • The underlying pathophysiology of cirrhotic cardiomyopathy is complex and not fully understood.
  • Existing knowledge gaps hinder the development of targeted therapeutic interventions.

Purpose of the Study:

  • To review cirrhotic cardiomyopathy from cellular and physiological perspectives.
  • To elucidate the mechanisms by which cirrhotic patients develop heart failure under stress.
  • To summarize current therapeutic options for cirrhotic cardiomyopathy.

Main Methods:

  • Literature review of cellular and physiological models of cirrhotic cardiomyopathy.
  • Analysis of pathophysiological changes including systolic, diastolic, and electrophysiological dysfunction.
  • Examination of heart failure development in response to stressors like infection and procedures.
  • Review of existing therapeutic modalities.

Main Results:

  • Pathophysiological changes in cirrhotic cardiomyopathy include systolic and diastolic dysfunction, and electrophysiological alterations.
  • Cirrhotic cardiomyopathy can manifest as overt heart failure during stressful conditions.
  • Therapeutic interventions for cirrhotic cardiomyopathy are currently limited.

Conclusions:

  • Cirrhotic cardiomyopathy is characterized by distinct cardiac dysfunctions.
  • Understanding the cellular and physiological basis is crucial for managing heart failure in cirrhosis.
  • Further research is needed to develop effective treatments for this condition.

More Related Videos

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...